So Fidelity have effectively bought a copy of Sonata to maintain themselves and will take on a small team of bravura developers.
The money being received will be paid out in the return of capital to investors.
This will mean that bravura will no longer have the recurring license revenue from fidelity going forward (albeit nor the costs of the development team).
my questions :
1. Why do fidelity want to go it alone rather than use bravura to support and maintain the software? Are they not happy with current arrangements?
2. Won’t this mean a lower recurring revenue for a company struggling to be considered “growth” going by the last few years revenue ?
3. Isn’t the strategy to generate more revenue from existing clients? This is kind of the opposite isn’t it?
doesn’t really look like a positive announcement to me.
- Forums
- ASX - By Stock
- BVS
- Ann: Bravura group signs agreement with Fidelity International
Ann: Bravura group signs agreement with Fidelity International, page-7
Featured News
Add BVS (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.49 |
Change
0.020(1.37%) |
Mkt cap ! $665.8M |
Open | High | Low | Value | Volume |
$1.47 | $1.49 | $1.44 | $509.9K | 345.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 22502 | $1.48 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.49 | 825 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 22502 | 1.475 |
2 | 1832 | 1.470 |
1 | 1828 | 1.465 |
1 | 1828 | 1.460 |
1 | 100000 | 1.440 |
Price($) | Vol. | No. |
---|---|---|
1.485 | 825 | 1 |
1.490 | 11868 | 6 |
1.495 | 12033 | 3 |
1.500 | 27141 | 4 |
1.550 | 1010 | 1 |
Last trade - 16.10pm 18/11/2024 (20 minute delay) ? |
Featured News
BVS (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
SPONSORED BY The Market Online